American Century Companies Inc. Sells 65,409 Shares of aTyr Pharma, Inc. $ATYR

American Century Companies Inc. reduced its position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) by 74.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,703 shares of the company’s stock after selling 65,409 shares during the quarter. American Century Companies Inc.’s holdings in aTyr Pharma were worth $69,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in aTyr Pharma during the 4th quarter worth about $17,677,000. Woodline Partners LP bought a new stake in shares of aTyr Pharma in the 4th quarter valued at about $6,092,000. Octagon Capital Advisors LP bought a new stake in shares of aTyr Pharma in the 4th quarter valued at about $3,258,000. Tang Capital Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter valued at about $2,430,000. Finally, Integral Health Asset Management LLC bought a new stake in shares of aTyr Pharma in the 4th quarter valued at about $1,358,000. 61.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on ATYR shares. Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Wells Fargo & Company boosted their target price on aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, June 20th. Finally, Jefferies Financial Group boosted their target price on aTyr Pharma from $9.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to data from MarketBeat, aTyr Pharma presently has an average rating of “Buy” and an average price target of $23.25.

aTyr Pharma Price Performance

Shares of ATYR opened at $5.61 on Monday. The stock has a market capitalization of $549.72 million, a P/E ratio of -7.01 and a beta of 1.01. aTyr Pharma, Inc. has a twelve month low of $1.67 and a twelve month high of $7.29. The company has a 50 day moving average of $5.34 and a 200-day moving average of $4.33. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). As a group, equities research analysts forecast that aTyr Pharma, Inc. will post -0.91 EPS for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.